1.Febrile illness (temperature � 38°C or 100.4°F) or any acute illness or infection within 4 <br/ >weeks of enrolment. <br/ >2. Laboratory confirmed SARS-CoV-2 positive. <br/ >3. History of contact with a confirmed active SARS-CoV-2 positive patient within 14 days. <br/ >4. History of SARS/ MERS infection. <br/ >5. Previous participation in any clinical trial of a SARS-CoV-2 candidate vaccine. <br/ >6. Past history of hypersensitivity reaction or any serious adverse event after any vaccination. <br/ >7. Past history of thrombocytopenia or any coagulation disorder, or subjects on anticoagulation <br/ >therapy. <br/ >8. Subjects with confirmed immunosuppressive or immunodeficiency disorder, or subjects on <br/ >any immunosuppressive or immunostimulant therapy. <br/ >9. Clinically significant systemic disorder such as cardiovascular, respiratory, neurologic, <br/ >gastrointestinal, hepatic, renal, endocrine, haematological, psychiatric or immunological <br/ >disorder. <br/ >10. Subjects administered blood, blood containing products or immunoglobulins within the last <br/ >3 months or planned administration during the study. <br/ >11. Any other vaccine administration within the last 30 days or planned to be administered <br/ >during the study period. <br/ >12. Pregnant and lactating women. <br/ >13. Participation in another clinical trial in the past 3 months. <br/ >14. History of drug / alcohol abuse.

1.Febrile illness (temperature � 38°C or 100.4°F) or any acute illness or infection within 4 <br/ >weeks of enrolment. <br/ >2. Laboratory confirmed SARS-CoV-2 positive. <br/ >3. History of contact with a confirmed active SARS-CoV-2 positive patient within 14 days. <br/ >4. History of SARS/ MERS infection. <br/ >5. Previous participation in any clinical trial of a SARS-CoV-2 candidate vaccine. <br/ >6. Past history of hypersensitivity reaction or any serious adverse event after any vaccination. <br/ >7. Past history of thrombocytopenia or any coagulation disorder, or subjects on anticoagulation <br/ >therapy. <br/ >8. Subjects with confirmed immunosuppressive or immunodeficiency disorder, or subjects on <br/ >any immunosuppressive or immunostimulant therapy. <br/ >9. Clinically significant systemic disorder such as cardiovascular, respiratory, neurologic, <br/ >gastrointestinal, hepatic, renal, endocrine, haematological, psychiatric or immunological <br/ >disorder. <br/ >10. Subjects administered blood, blood containing products or immunoglobulins within the last <br/ >3 months or planned administration during the study. <br/ >11. Any other vaccine administration within the last 30 days or planned to be administered <br/ >during the study period. <br/ >12. Pregnant and lactating women. <br/ >13. Participation in another clinical trial in the past 3 months. <br/ >14. History of drug / alcohol abuse.

N/A

N/A

1.Febrile illness (temperature � 38°C or 100.4°F) or any acute illness or infection within 4 <br/ >weeks of enrolment. <br/ >2. Laboratory confirmed SARS-CoV-2 positive. <br/ >3. History of contact with a confirmed active SARS-CoV-2 positive patient within 14 days. <br/ >4. History of SARS/ MERS infection. <br/ >5. Previous participation in any clinical trial of a SARS-CoV-2 candidate vaccine. <br/ >6. Past history of hypersensitivity reaction or any serious adverse event after any vaccination. <br/ >7. Past history of thrombocytopenia or any coagulation disorder, or subjects on anticoagulation <br/ >therapy. <br/ >8. Subjects with confirmed immunosuppressive or immunodeficiency disorder, or subjects on <br/ >any immunosuppressive or immunostimulant therapy. <br/ >9. Clinically significant systemic disorder such as cardiovascular, respiratory, neurologic, <br/ >gastrointestinal, hepatic, renal, endocrine, haematological, psychiatric or immunological <br/ >disorder. <br/ >10. Subjects administered blood, blood containing products or immunoglobulins within the last <br/ >3 months or planned administration during the study. <br/ >11. Any other vaccine administration within the last 30 days or planned to be administered <br/ >during the study period. <br/ >12. Pregnant and lactating women. <br/ >13. Participation in another clinical trial in the past 3 months. <br/ >14. History of drug / alcohol abuse.

1.Febrile illness (temperature � 38°C or 100.4°F) or any acute illness or infection within 4 <br/ >weeks of enrolment. <br/ >2. Laboratory confirmed SARS-CoV-2 positive. <br/ >3. History of contact with a confirmed active SARS-CoV-2 positive patient within 14 days. <br/ >4. History of SARS/ MERS infection. <br/ >5. Previous participation in any clinical trial of a SARS-CoV-2 candidate vaccine. <br/ >6. Past history of hypersensitivity reaction or any serious adverse event after any vaccination. <br/ >7. Past history of thrombocytopenia or any coagulation disorder, or subjects on anticoagulation <br/ >therapy. <br/ >8. Subjects with confirmed immunosuppressive or immunodeficiency disorder, or subjects on <br/ >any immunosuppressive or immunostimulant therapy. <br/ >9. Clinically significant systemic disorder such as cardiovascular, respiratory, neurologic, <br/ >gastrointestinal, hepatic, renal, endocrine, haematological, psychiatric or immunological <br/ >disorder. <br/ >10. Subjects administered blood, blood containing products or immunoglobulins within the last <br/ >3 months or planned administration during the study. <br/ >11. Any other vaccine administration within the last 30 days or planned to be administered <br/ >during the study period. <br/ >12. Pregnant and lactating women. <br/ >13. Participation in another clinical trial in the past 3 months. <br/ >14. History of drug / alcohol abuse.